Pembrolizumab

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells. The ligands for PD-1 include programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs. Activated PD-1 negatively regulates T-cell activation and plays a key role in in tumor evasion from host immunity.

**Synonyms:** - BCD-201 - GME 751 - GME751 - Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S>P))gamma 4 Heavy Chain (134-218')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'':229-229'')-bisdisulfide - Keytruda - Lambrolizumab - MK 3475 - MK-3475 - MK3475 - PEMBROLIZUMAB - Pembrolizumab Biosimilar BCD-201 - Pembrolizumab Biosimilar GME751 - Pembrolizumab Biosimilar QL2107 - Pembrolizumab Biosimilar RPH-075 - Pembrolizumab Biosimilar SB27 - QL2107 - RPH 075 - RPH-075 - RPH075 - SB 27 - SB-27 - SB27 - SCH 900475 - SCH-900475 - SCH900475 - pembrolizumab